A Phase II, Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type.
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2019
Price : $35 *
At a glance
- Drugs Donepezil/solifenacin (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Therapeutic Use
- Sponsors Chase Pharmaceuticals
- 06 Feb 2018 Status changed from active, no longer recruiting to completed.
- 21 Jul 2017 Planned End Date changed from 1 Dec 2016 to 1 Sep 2017.
- 21 Jul 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Sep 2017.